Lexicon Pharmaceuticals Inc (LXRX)

Jan 21, 2025

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - NRToday.com

Jan 21, 2025

Jan 21, 2025

Lexicon Pharma to Host Expert Panel on Groundbreaking Non-Opioid Pain Treatment LX9211 - StockTitan

Jan 21, 2025

Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025

Jan 08, 2025

Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com India

Jan 08, 2025

Jan 07, 2025

Lexicon Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Nigeria

Jan 07, 2025

Jan 07, 2025

Strong week for Lexicon Pharmaceuticals (NASDAQ:LXRX) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Jan 07, 2025

Jan 06, 2025

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey

Jan 06, 2025

Jan 03, 2025

Lexicon Pharmaceuticals, Inc. Appoints Scott M. Coiante as Senior Vice President - Marketscreener.com

Jan 03, 2025

Jan 03, 2025

Lexicon Pharmaceuticals, Inc. Announces CFO Changes - Marketscreener.com

Jan 03, 2025

Jan 02, 2025

Lexicon Pharmaceuticals, Inc. Appoints Scott Coiante as Senior Vice President - Marketscreener.com

Jan 02, 2025

Jan 02, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times

Jan 02, 2025

Jan 02, 2025

Lexicon Pharmaceuticals Names Scott Coiante Finance Chief - MarketWatch

Jan 02, 2025

Jan 02, 2025

Lexicon Pharma (LXRX) Appoints Scott Coiante as CFO - StreetInsider.com

Jan 02, 2025

Jan 02, 2025

Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan

Jan 02, 2025

Dec 31, 2024

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lexicon Pharmaceuticals, Inc. (LXRX), ProShares Short VIX Short-Term Futures ETF (SVXY) & Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Cor - AccessWire

Dec 31, 2024

Dec 30, 2024

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33% - Yahoo Finance

Dec 30, 2024

Dec 23, 2024

Lexicon Zynquista vista narrows with diabetes CRL; gain due in pain? - BioWorld Online

Dec 23, 2024

Dec 23, 2024

Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat

Dec 23, 2024

Dec 23, 2024

Analyst Expectations For Lexicon Pharmaceuticals's Future - Benzinga

Dec 23, 2024

Dec 21, 2024

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - The Manila Times

Dec 21, 2024

Dec 20, 2024

Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista? (sotagliflozin) - Marketscreener.com

Dec 20, 2024

Dec 20, 2024

Stocks to Watch: Rumble, Lexicon Pharmaceuticals - MarketWatch

Dec 20, 2024

Dec 20, 2024

FDA rejects Lexicon's Zynquista for diabetes, kidney disease - Seeking Alpha

Dec 20, 2024

Dec 20, 2024

US FDA declines to approve Lexicon Pharma's add-on diabetes drug - Reuters

Dec 20, 2024

Dec 20, 2024

Lexicon Pharma Receives FDA Rejection for Diabetes Drug Zynquista, Shifts Focus to Pain Treatment Pipeline - StockTitan

Dec 20, 2024

Dec 18, 2024

Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Sector Weakness - GuruFocus.com

Dec 18, 2024

Dec 11, 2024

Hypertrophic Cardiomyopathy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Edgewise Therapeutics, Novartis, Lexicon Pharma, Shandong Suncadia Medicine, Ji Xing Pharma - Barchart

Dec 11, 2024

Dec 10, 2024

Point72 Asset Management L.P. Sells 2,891,141 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat

Dec 10, 2024

Dec 09, 2024

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - Business Wire

Dec 09, 2024

Dec 06, 2024

Fmr LLC Has $78.29 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat

Dec 06, 2024

Dec 05, 2024

Lexicon Pharmaceuticals (LXRX) Stock Dips Amid Market Volatility - GuruFocus.com

Dec 05, 2024

Dec 04, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $0.73 By Investing.com - Investing.com South Africa

Dec 04, 2024

Dec 03, 2024

Lexicon Pharmaceuticals stock hits 52-week low at $0.73 - Investing.com India

Dec 03, 2024

Dec 02, 2024

Biotech Stocks Facing FDA Decision In December 2024 - RTTNews

Dec 02, 2024

Nov 30, 2024

Braidwell LP Sells 7,493,366 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - MarketBeat

Nov 30, 2024

Nov 28, 2024

Lexicon completes subject enrolment for DPNP trial of LX9211 - Clinical Trials Arena

Nov 28, 2024

Nov 27, 2024

2 Generic Drug Stocks Ready to Surge in 2025 - Benzinga

Nov 27, 2024

Nov 27, 2024

The Escalator: Lexicon Pharmaceuticals, Reckitt, NIH and more - MM+M Online

Nov 27, 2024

Nov 26, 2024

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times

Nov 26, 2024

Nov 26, 2024

Lexicon Pharma Hits 120% Enrollment Target in Key Pain Drug Trial, Ahead of Schedule | LXRX Stock News - StockTitan

Nov 26, 2024

Nov 26, 2024

Lexicon Pharmaceuticals to Participate in December Investor Conferences - The Manila Times

Nov 26, 2024

Nov 25, 2024

Lexicon Pharmaceuticals CEO to Present at Two Major Healthcare Conferences in December | LXRX Stock News - StockTitan

Nov 25, 2024

Nov 25, 2024

Lexicon Pharmaceuticals shares target cut, retains buy rating on FDA letter - Investing.com UK

Nov 25, 2024

Nov 25, 2024

Lexicon pivots back to pipeline after FDA rejection - The Pharma Letter

Nov 25, 2024

Nov 23, 2024

Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives "Hold" Rating from Needham & Company LLC - MarketBeat

Nov 23, 2024

Nov 22, 2024

Lexicon Pharmaceuticals to cut 60% of workforce By Investing.com - Investing.com South Africa

Nov 22, 2024

Nov 22, 2024

Lexicon Pharmaceuticals to cut 60% of workforce - Investing.com India

Nov 22, 2024

Nov 22, 2024

Lexicon Cuts Commercial Operation, Focuses On R&D After FDA Letdown - Citeline News & Insights

Nov 22, 2024